Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared a post on X:
”Press release just in time to make things more interesting for ASCO24 – Datopotamab deruxtecan showed ‘clinically meaningful’ overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial.”
Read further.
Source: Gilberto Lopes/X